SC
FOMX

Steven Cohen’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Steven Cohen’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,154,680
Closed -$6.62M – 1331
2018
Q3 		$6.62M Buy
+1,154,680
New +$6.61M 0.03% 538

Other funds holding FOMX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Steven Cohen's FOMX Position: Q4 2018 in Review

Steven Cohen sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2018, closing a stake of 1,154,680 shares — an estimated $6.62M sold.

Steven Cohen first reported a position in FOMX in Q3 2018 and held it in 1 quarter. The position peaked at $6.62M in Q3 2018. 66 funds tracked by Wall St. Rank hold FOMX as of Q4 2018.

  • Steven Cohen reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Steven Cohen sold 1,154,680 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2018, an estimated $6.62M.
  • Steven Cohen first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2018 and held it in 1 quarter.
  • Steven Cohen's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $6.62M in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2018.

Based on Point72 Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.